Valneva SE (VALN)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $5.56
- As of
Kresmion compiles this page from VALN's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Valneva SE (VALN): 2 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 6-K filed 2026-10-08.
See the full VALN dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for VALN on one page. Preview it with sample data, then open it live with a free account.
Preview the VALN dossierActive signals for VALN
- mediumEARNINGS_MISS
Q2-2026: Missed consensus by 243.3%, EPS $-0.3468 vs $-0.101 estimate
- mediumNEW_POSITION
MILLENNIUM MANAGEMENT LLC new position in VALN
- mediumEARNINGS_BEAT
Q2-2025: Beat consensus by 56.7% - EPS $-0.07 vs $-0.1616 estimate
- mediumEARNINGS_MISS
Q3-2025: Missed consensus by 90.6% - EPS $-0.26 vs $-0.1364 estimate
- mediumEARNINGS_MISS
Q4-2025: Missed consensus by 36.7% - EPS $-0.29 vs $-0.2121 estimate
FREE, NO ACCOUNT
Every signal on VALN, as it fires
You are seeing 5 of 6 signals recorded on VALN since 2026-05-29.
The five above landed across 3 days. The other 1 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in VALN (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLCCUSIP 92025Y103 · 2026Q2 | $707K | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 92025Y103 · 2026Q2 | $106K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, VALN
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
VALN against its peers
VALN's operating margin of -47.0% ranks in the 65th percentile of 12 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | VALN | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 175M EUR | n/a | n/a | 0 |
| Revenue YoY | 3.0% | n/a | n/a | 0 |
| Operating margin | -47.0% | -299.3% | 65 | 12 |
| Net margin | -66.0% | -302.3% | 65 | 12 |
| Return on equity | -108.5% | -42.6% | 17 | 20 |
| 1 year | n/a | -13.9% | n/a | 20 |
Peers (22): CTMX, SLN, CRMD, PHAT, CBIO, NVCT, DBVT, SGMT, PBYI, ALLO, STTK, RGNX, MNPR, IRWD, CLYM, AURA, ALT, OCS, MPLT, NGNE, WVE, OLMA. Left out: ETRA (no annual filing), DRUG (period gap), BLSM (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (VALN: 20-F), reported in EUR. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow VALN on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to VALN for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.